biopharmapatent

Friday, January 13, 2017

Supreme Court Takes Up Amgen-Sandoz Biosimilar Brawl

http://bit.ly/2jNnhYe
Posted by Paul Moradian's Pharma blog at 12:09 PM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

LinkedIn

Blog Archive

  • ►  2020 (2)
    • ►  August (1)
    • ►  April (1)
  • ►  2019 (5)
    • ►  January (5)
  • ►  2018 (4)
    • ►  December (1)
    • ►  October (1)
    • ►  August (1)
    • ►  July (1)
  • ▼  2017 (63)
    • ►  December (2)
    • ►  November (2)
    • ►  October (2)
    • ►  August (5)
    • ►  July (9)
    • ►  June (4)
    • ►  May (10)
    • ►  April (4)
    • ►  March (13)
    • ►  February (7)
    • ▼  January (5)
      • Method Infringed Despite Patient Performing One of...
      • HUMIRA PATENT EXPIRATION DATES
      • Supreme Court Takes Up Amgen-Sandoz Biosimilar Brawl
      • BIOSIMILAR IPR STATUS UPDATE (BIOSIMILAR INTER PAR...
      • AbbVie: Humira’s patent maze will keep US biosimil...
  • ►  2016 (23)
    • ►  December (5)
    • ►  November (6)
    • ►  October (3)
    • ►  September (9)

About Me

Paul Moradian's Pharma blog
View my complete profile
Payam Moradian's blog. Simple theme. Powered by Blogger.